<DOC>
	<DOCNO>NCT00366327</DOCNO>
	<brief_summary>An open-label extension study use variable dose ( 20 30 mg daily ) bifeprunox evaluate long-term safety .</brief_summary>
	<brief_title>Study Evaluating Bifeprunox Patients With Schizophrenia .</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Outpatients successfully complete Wyeth study 3168A1313 . 2 . A signed date informed consent form study . 3 . No major protocol violation previous study . 1 . Clinically important abnormality precede shortterm study resolve . 2 . Use prohibit treatment precede shortterm study . 3 . Meeting exclusion criterion precede shortterm study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>